Previous 10 | Next 10 |
home / stock / lly / lly articles
BofA Securities analyst Geoff Meacham reiterated the Buy rating on Eli Lilly And Company (NYSE:LLY), with a price forecast of $1,000. An advisory c...
As of June 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in th...
Eli Lilly And Co’s (NYSE:LLY) shares are trading higher after an advisory committee to the U.S. Food and Drug Administration (FDA) delivered ...
Eli Lilly and Co (NYSE:LLY) shared detailed results from the SYNERGY-NASH phase 2 study on Saturday. This trial involved 190 patients, both with an...
U.S. District Judge Karen Marston in Philadelphia is set to preside over litigation involving the popular diabetes and weight-loss drugs Ozempic, W...
With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have s...
The rise of weight loss drugs like Wegovy and Mounjaro by Novo Nordisk (NYSE:NVO) is leading to new product developments across various sectors. Wh...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
On Monday, June 10, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee will meet to discuss and vote on whether the dat...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-18 05:23:00 ET Stock splits can sometimes be an effective way for a company to generate excitement around its stock. It's a sign that the company is doing well, and by lowering the price of the stock through a split, the shares can become more accessible to a wider pool of investo...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...